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Efficacy of denosumab with regard to bone
destruction in prognostic subgroups of
Japanese rheumatoid arthritis patients from
the phase II DRIVE study
Naoki Ishiguro1, Yoshiya Tanaka2, Hisashi Yamanaka3, Toshiyuki Yoneda4,
Takeshi Ohira5, Naoki Okubo5, Harry K. Genant6, De´sire´e van der Heijde7 and
Tsutomu Takeuchi8
Abstract
Objectives. To evaluate the efficacy of denosumab for progressive bone erosion in risk factor subgroups of Japanese
RA patients.
Methods. This study included 340 RA patients on MTX from the dose-response study of Denosumab in patients with
RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE study-a 12-month, multicentre,
randomized, double-blind, placebo-controlled, phase II study). The patients were randomized to receive placebo or
denosumab 60 mg every 6 months, 3 months or 2 months. Subgroup analyses involved baseline RF, ACPA, swollen
joint count, CRP level, RA duration, ESR and glucocorticoid use.
Results. Patients with risk factor positivity generally showed consistent results for the primary endpoint of the change in
the modified Sharp erosion score at 12 months from baseline. In the placebo, every 6 months, every 3 months and every
2 months groups, the mean changes in the erosion score, according to the RF status (RF-positive vs -negative sub-
groups), were 1.18 vs 0.59, 0.25 (P = 0.0601 vs placebo) vs 0.31 (P = 0.0827), 0.21 (P = 0.0422) vs 0.02 (P = 0.0631) and
0.15 (P = 0.0010) vs 0.05 (P = 0.0332), respectively, while the mean changes in the erosion score, according to the
ACPA status (ACPA-positive vs -negative subgroups), were 1.30 vs 0.07, 0.26 (P = 0.0142) vs 0.33 (P = 0.2748), 0.16 (P =
0.0058) vs 0.08 (P = 0.7166) and 0.09 (P < 0.0001) vs 0.08 (P = 0.8939), respectively.
Conclusion. Denosumab is a potentially useful treatment option for RA patients who are positive for RF, ACPA and
other possible risk factors.
Trial registration. JAPIC Clinical Trials Information, http://www.clinicaltrials.jp/user/cteSearch_e.jsp, JapicCTI-101263.
Key words: rheumatoid arthritis, denosumab, bone erosion, subgroup analysis, rheumatoid factor, anti-cyclic
citrullinated peptide antibody
Rheumatology key messages
. RF and ACPA are prognostic factors that predict progressive bone erosion in RA patients.
. Denosumab effectively prevents bone erosion progression in patients receiving MTX with these risk factors.
. Denosumab is expected to show reliable efficacy in patients with extensive erosion progression.
Introduction
RA is a chronic disease characterized by persistent syno-
vitis, systemic inflammation and joint destruction [1]. One
of the causes of bone erosion and bone loss is increased
osteoclast activity [2]. M-CSF and receptor activator of
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nuclear factor kB (RANK) ligand (RANKL) are considered
to be essential for osteoclast differentiation, activation and
survival [37]. Denosumab is a fully human mAb that binds
specifically to human RANKL and inhibits bone resorption
[8]; thus, it is expected to prevent the progression of bone
erosion and bone loss.
We previously reported the efficacy of denosumab with
regard to the inhibition of bone erosion among Japanese
RA patients in the dose-response study of Denosumab in
patients with RheumatoId arthritis on methotrexate to
Validate inhibitory effect on bone Erosion (DRIVE study),
which was a 12-month, multicentre, randomized, double-
blind, placebo-controlled, phase II study of denosumab
administered subcutaneously at a dosage of 60 mg
every 6 months (Q6M), 3 months (Q3M) or 2 months
(Q2M) with MTX [9]. The results indicated that denosumab
inhibited the progression of bone erosion. However, dif-
ferences in the treatment response according to sub-
groups based on the bone erosion progression risk
factor status have not been reported. Previous studies
have reported that poor prognostic factors, such as RF
and ACPA, are risk factors for the progression of radio-
graphic erosion in RA patients [10, 11]. In the present
study, we focused on the results of subgroups that had
poor prognostic factors in the DRIVE study. We grouped
patients according to the swollen joint count (SJC) and
CRP level, in addition to RF and ACPA, because these
have been reported as risk factors for bone destruction
[1214]. The primary objective of this subgroup analysis
was to evaluate the effect of denosumab on bone erosion
progression among RA patients in risk factor subgroups.
Methods
Patients and study design
The eligibility criteria and design of this study have been
described in detail in our previous report [9]. It is important
to note that, at registration, we excluded patients who were
orally administered Bisphosphonates (BPs) for a total of
2 years (104 weeks) or more in the past, as well as patients
who were intravenously administered BPs in the past.
Patients were randomly registered under a double-blind
design to subcutaneously receive either placebo or deno-
sumab 60 mg Q6M, Q3M or Q2M. Randomization was
stratified according to glucocorticoid use and RF status
at baseline. All patients basically continued MTX treat-
ment (616 mg/week) with vitamin D5400 IU and calcium
5600 mg/day. The investigators were allowed to pre-
scribe bucillamine, salazosulfapyridine, glucocorticoid
and/or NSAIDs at any time throughout the study. Patient
eligibility depended on a diagnosis of RA by the investi-
gator and fulfilment of the 1987 American College of
Rheumatology (ACR) criteria [15], with RA disease dur-
ation of 6 months to <5 years and at least 6 swollen
joints among a total of 58 joints assessed by the investi-
gator at screening. For enrolment, patients also had to
demonstrate radiographic bone erosion as assessed by
the investigator or meet the following criteria at screening:
CRP level 51.0 mg/dl or ESR 528 mm/h, and ACPA
positivity or RF level >20 IU/ml. The main exclusion criter-
ion was previous or current use of biologics for the treat-
ment of RA. The use of bisphosphonates and oral
glucocorticoids at a dose of >10 mg/day (prednisolone
equivalent) was prohibited throughout the study.
This study was approved by the institutional review
board of each participating institution and was conducted
in accordance with the principles of the Declaration of
Helsinki. Written informed consent was obtained from all
participants.
Radiographic assessment
Radiographs of the hands, wrists and feet, obtained at
baseline and at 6 and 12 months, were assessed according
to the van der Heijde modified Sharp method [16]. Two well-
trained readers who were blinded to the treatment groups,
patient characteristics and time order evaluated the images.
The average scores of the two readers were used for ana-
lyses. The changes in the modified Sharp erosion score
from baseline were calculated at 6 and 12 months.
Statistical analysis
Changes in the erosion score at 12 months were analysed
according to subgroups based on the RF status (positive or
negative), ACPA status (positive or negative), baseline SJC
(<10 or510), baseline CRP level (<1.0 or51.0 mg/dl), RA
duration (<3 or53 years, this cut-off indicates early RA or
not), glucocorticoid use (absence or presence) and baseline
ESR (<28 or 528 mm/h). Two-sided van Elteren stratified
rank tests, adjusting for randomized strata (four strata ac-
cording to the combination of baseline glucocorticoid use
and baseline RF), were performed for comparisons be-
tween the denosumab groups and placebo group with
regard to changes in the radiographic score. In post hoc
analysis, the proportion of patients without radiographic
progression (change in the erosion score from baseline
40.5) and the proportion of patients with rapid erosion
progression (change in the erosion score from baseline
53.0 or 55.0) among patients in risk factor subgroups
were analysed using Fisher’s exact test.
Efficacy endpoints were analysed using the full analysis
set that included all randomized patients who received
at least one dose of denosumab or placebo and had a
baseline radiographic score, as well as at least one
post-baseline radiographic score. Missing values for the
radiographic scores were imputed using linear extrapola-
tion/interpolation. All statistical analyses were performed
using SAS software (release 9.2; SAS Institute, Inc., Cary,
NC, USA). The significance level was set at 0.05.
Results
Baseline characteristics and patient disposition
The study included 340 RA patients. Baseline demograph-
ics and characteristics were generally comparable
between the treatment groups [9].
The mean (S.D.) patient ages were 57.0 (10.57) years in
the placebo group, 54.4 (10.57) years in the Q6M group,
52.0 (11.65) years in the Q3M group and 54.6 (10.51) years
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in the Q2M group. However, the proportion of female pa-
tients was slightly higher in the placebo group (86.4%)
than in the other groups (76.5% in the Q6M group,
72.0% in the Q3M group and 77.6% in the Q2M group).
Radiographic progression
Denosumab significantly inhibited the progression of bone
erosion at 12 months when compared with the progres-
sion on placebo treatment in the overall population of the
DRIVE study. The mean changes in the modified Sharp
erosion score at 12 months from baseline in the placebo,
Q6M, Q3M and Q2M groups were 0.99, 0.27 (P = 0.0082
vs placebo), 0.14 (P = 0.0036) and 0.09 (P < 0.0001), re-
spectively [9].
The score change was greater among RF-positive pa-
tients than among RF-negative patients in the placebo
group. On the other hand, the difference in the score
change between RF-positive and RF-negative patients
was less pronounced in the denosumab groups (Fig. 1A
and B). A similar tendency was noted for ACPA (Fig. 1C
and D).
Changes in the modified Sharp erosion score were numer-
ically smaller among RF-positive patients in all denosumab
groups than in the placebo group (Fig. 1A and Table 1). The
difference between the placebo and Q3M or Q2M groups
was statistically significant; however, the difference between
the placebo and Q6M groups was not significant. Similarly,
the changes were numerically and significantly smaller
among ACPA-positive patients in all denosumab groups
than in the placebo group (Fig. 1C and Table 1). Changes
in the bone erosion score among denosumab-treated
patients decreased dose-dependently in the RF- and
ACPA-positive subgroups. These results are consistent with
the primary endpoint in the overall population [the mean
changes in the bone erosion score in the placebo, Q6M,
Q3M and Q2M groups were 0.99 (95% CI 0.42, 1.56), 0.27
(0.06, 0.48, P = 0.0082 vs placebo), 0.14 (0.02, 0.26, P =
0.0036) and 0.09 (0.24, 0.41, P < 0.0001), respectively].
On the other hand, the difference in the score between
the placebo group and the Q6M, Q3M or Q2M group was
numerically lower among RF-negative patients than among
RF-positive patients, while a significant difference was
observed for only the Q2M group (Fig. 1B and Table 1).
FIG. 1 Mean change in modified Sharp erosion score from baseline to 12 months in the subgroups
(A) RF-positive subgroup, (B) RF-negative subgroup, (C) ACPA-positive subgroup and (D) ACPA-negative subgroup. The
means ± S.E.M. are presented. P-values were calculated using the two-sided van Elteren stratified rank test adjusted for
randomized strata (four strata according to the combination of baseline glucocorticoid use and baseline RF) vs placebo.
Q2M: denosumab 60 mg every 2 months; Q3M: denosumab 60 mg every 3 months; Q6M: denosumab 60 mg every 6
months.
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Additionally, among ACPA-negative patients, no numeri-
cal or significant differences were observed be-
tween the placebo and denosumab groups (Fig. 1D and
Table 1).
The proportion of patients with rapid erosion progres-
sion (change in erosion score 53 or 55) was larger
among RF-positive patients than among RF-negative pa-
tients in the placebo group (Table 2). The proportion
decreased in the denosumab groups, regardless of the
baseline RF status; however, statistical significance was
observed only for erosion score 53 in the RF-positive
subgroup. With regard to the subgroups according to
the baseline ACPA status, only ACPA-positive patients
in the placebo group showed rapid erosion progression.
The proportion of patients with a change in erosion score
53 was significantly lower in the denosumab groups than
in the placebo group (Table 2). The cumulative probability
plots of changes in the erosion score showed that the
proportion of patients without radiographic progression
was quantitatively larger in all denosumab groups than
in the placebo group among the RF-positive, RF-negative
and ACPA-positive subgroups, but not the ACPA-negative
subgroup (Fig. 2).
Furthermore, we performed subgroup analysis involving
other potential prognostic factors. Changes in the bone
erosion score were smaller in the denosumab groups
than in the placebo group among all subgroups that
were based on factors such as baseline SJC, baseline
CRP level, RA duration and baseline ESR status (Table 3
and supplementary Figs S1S4, available at
Rheumatology online). A numerically great change in the
erosion scores of patients in the placebo group was
observed in the patients with a baseline SJC 510, base-
line CRP level51.0 mg/dl, RA duration53 years or base-
line ESR 528 mm/h. However, significant differences
were only observed in the Q3M and Q2M groups,
among patients with a baseline SJC 510 and in the
Q2M group among those with a baseline ESR 528 mm/
h. With regard to the counterpart subgroups (i.e. baseline
SJC <10, baseline CRP level <1.0 mg/dl, RA duration
<3 years and baseline ESR <28 mm/h) that showed a
small change (around 0.5) in the bone erosion score in
the placebo group, significant decreases in the score
were observed in all denosumab groups, excluding the
Q6M group, among patients with an RA duration <3 years.
In addition, subgroup analysis involving glucocorticoid
use (one of the stratification factors) was performed. In the
placebo group, bone erosion progression was greater
among patients with basal glucocorticoid use than
among those without glucocorticoid use (Table 3 and
TABLE 1 Changes in erosion score from baseline to 12 months, according to RF and ACPA status
Denosumab
Placebo (N=88) 60 mg Q6M (N=85) 60 mg Q3M (N=82) 60 mg Q2M (N=85)
RF status
Positive
n 60 59 56 57
Mean (S.D.) 1.18 (3.08) 0.25 (0.73) 0.21 (0.55) 0.15 (1.83)
Median (Q1, Q3) 0.00 (0.00, 1.00) 0.000 (0.00, 0.50) 0.000 (0.00, 0.00) 0.000 (0.00, 0.00)
P-value  0.0601 0.0422 0.0010
Negative
n 28 26 26 28
Mean (S.D.) 0.59 (1.53) 0.31 (1.41) 0.02 (0.46) 0.05 (0.44)
Median (Q1, Q3) 0.00 (0.00, 0.50) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)
P-value  0.0827 0.0631 0.0332
ACPA status
Positive
n 66 70 64 65
Mean (S.D.) 1.30 (3.04) 0.26 (0.75) 0.16 (0.57) 0.09 (1.73)
Median (Q1, Q3) 0.00 (0.00, 1.50) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)
P-value  0.0142 0.0058 <0.0001
Negative
n 22 15 18 20
Mean (S.D.) 0.07 (0.23) 0.33 (1.73) 0.08 (0.39) 0.08 (0.37)
Median (Q1, Q3) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)
P-value  0.2748 0.7166 0.8939
The erosion score was assessed using the van der Heijde modified Sharp method. P-values were calculated using the two-
sided van Elteren stratified rank test adjusted for randomized strata (four strata according to the combination of baseline
glucocorticoid use and baseline RF) vs placebo. Q2M: denosumab 60 mg every 2 months; Q3M: denosumab 60 mg every
3 months; Q6M: denosumab 60 mg every 6 months; N: number of patients who received 51 dose of the investigational
product and had baseline measurement and at least one post-baseline measurement of the radiographic score; n: number
of patients in the subgroup; Q1, Q3: quartile 1, 3.
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supplementary Fig. S5, available at Rheumatology online).
Denosumab effectively reduced the mean change in the
erosion score in both subgroups. Among patients with
glucocorticoid use, a significant reduction in the erosion
score was observed only in the Q2M group, while among
patients in all denosumab groups without glucocorticoid
use, a significant reduction was observed.
Discussion
Bone erosion is a central clinical feature of RA and is
associated with enhanced osteoclast differentiation sti-
mulated by two essential mediators (M-CSF and RANKL)
[3]. Denosumab, an anti-RANKL antibody, was found to
be effective for bone erosion; however, it likely has no
effect on disease activity [9, 17]. In this study, we evalu-
ated the efficacy of denosumab with regard to the pro-
gression of bone erosion in patients receiving MTX among
subgroups positive for the risk factors of progression,
such as RF, ACPA status, baseline SJC and CRP level.
The results were generally consistent for the primary
endpoint, with regard to the overall population of the
DRIVE study. Additionally, the quantitative trend of
dose-dependent inhibition in the risk factor subgroups
was consistent with the result in the overall population.
However, there were differences among the subgroups
according to the presence/absence of the risk factors of
progression in, not only the placebo group, but also the
denosumab groups.
Previous studies have shown that positive RF and
ACPA findings are risk factors for bone erosion pro-
gression in patients with RA [11, 12]. Our results are
consistent with these findings. Radiographic progres-
sion at 12 months was much greater among RF-positive
and ACPA-positive patients than among negative pa-
tients, especially in the placebo group. Denosumab
showed a potent inhibitory effect on bone erosion in a
dose-dependent manner among RF-positive and
ACPA-positive patients. Thus, denosumab is con-
sidered as a treatment option for RA patients with
bone erosion progression, despite a positive RF and/
or ACPA status.
The present study also evaluated the efficacy of deno-
sumab in RF-negative and ACPA-negative patients, who
may experience only limited progression of joint destruc-
tion. Denosumab did not show a clear effect in these
patients. Accordingly, these patients do not appear to
benefit from denosumab treatment. However, the as-
sessment of negative subgroups involved small sample
sizes; thus, the findings should be interpreted with cau-
tion. Moreover, the disease activity of patients in this
study was lower than that of patients in clinical studies
involving other biologics [1820]. It is likely that the in-
vestigators controlled the disease activity well in this
TABLE 2 Proportion of patients with rapid erosion progression within the subgroups (RF and ACPA status)
Change in erosion score 53 Change in erosion score 55
n (%) P-value n (%) P-value
RF status
Positive
Placebo (N = 60) 8 (13.3)  4 (6.7) 
60 mg Q6M (N = 59) 0 (0.0) 0.0061 0 (0.0) 0.1187
60 mg Q3M (N = 56) 0 (0.0) 0.0063 0 (0.0) 0.1194
60 mg Q2M (N = 57) 1 (1.8) 0.0325 1 (1.8) 0.3649
Negative
Placebo (N = 28) 3 (10.7)  1 (3.6) 
60 mg Q6M (N = 26) 2 (7.7) 1.0000 1 (3.8) 1.0000
60 mg Q3M (N = 26) 0 (0.0) 0.2369 0 (0.0) 1.0000
60 mg Q2M (N = 28) 0 (0.0) 0.2364 0 (0.0) 1.0000
ACPA status
Positive
Placebo (N = 66) 11 (16.7)  5 (7.6) 
60 mg Q6M (N = 70) 1 (1.4) 0.0018 0 (0.0) 0.0248
60 mg Q3M (N = 64) 0 (0.0) 0.0006 0 (0.0) 0.0579
60 mg Q2M (N = 65) 1 (1.5) 0.0043 1 (1.5) 0.2079
Negative
Placebo (N = 22) 0 (0.0)  0 (0.0) 
60 mg Q6M (N = 15) 1 (6.7) 0.4054 1 (6.7) 0.4054
60 mg Q3M (N = 18) 0 (0.0)  0 (0.0) 
60 mg Q2M (N = 20) 0 (0.0)  0 (0.0) 
P-values were calculated using Fisher’s exact test. N: number of patients who received 51 dose of the investigational product
and had baseline measurement and at least one post-baseline measurement of the radiographic score in the subgroup; n:
number of patients with an erosion score 53 or 55.
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study, as they could adjust the dosage of MTX
within approved limits and prescribe salazosulfapyridine
and/or bucillamine as needed throughout the study
period. Nevertheless, 17.9 and 4.5% of patients experi-
enced ongoing bone erosion (score >0.5) in the RF-
negative and ACPA-negative subgroups of the placebo
group, respectively. However, denosumab was shown to
reduce this proportion. Previous studies reported that
erosion progresses in patients who have not achieved
remission, despite control of disease activity with con-
ventional synthetic DMARDs [21, 22]. In addition, a sub-
stantial proportion of patients treated with MTX
monotherapy show rapid radiographic progression des-
pite RF and/or ACPA negativity [13]. Thus, the current
prognostic risk factors are not sufficient to identify pro-
gressive patients, and it remains unclear whether deno-
sumab is beneficial for RA patients with a low risk for
progressive bone erosion.
Denosumab was significantly effective at all assessed
doses among patients with a baseline SJC 510, base-
line CRP <1.0 mg/dl, RA duration <3 years, baseline ESR
<28 mm/h and no glucocorticoid use. However, in con-
trast to the subgroups with the RF and ACPA status, the
changes in bone destruction were smaller among these
subgroups in the placebo group. In this study, only RF
and glucocorticoid use were stratification factors, while
the treatment assigned within these subgroups was
balanced for known and unknown prognostic factors.
The other subgroups were created post hoc, so there
may exist an imbalance in the other prognostic factors.
Additionally, interactions between the subgroups were
not assessed because of the small sample size.
Therefore, the statistical results of this study should be
interpreted carefully.
The present study had some limitations. First, the treat-
ment duration was relatively short (12 months). Second,
the sample size was small, resulting in seemingly under-
powered significance analyses in some subgroups.
Finally, only a partial post hoc analysis was performed
(proportions of patients without radiographic progression
and rapid radiographic progression in the DRIVE study).
In conclusion, RF and ACPA are poor prognostic factors
and denosumab is a potentially useful treatment option for
RA patients receiving MTX with these factors. Although
denosumab was found to reduce the proportion of pro-
gressive patients in the risk factor-negative subgroups, a
further clinical trial with an adequate sample size is
required to confirm the findings.
FIG. 2 Cumulative probability plot of the change from baseline to 12 months in the subgroups
(A) RF-positive subgroup, (B) RF-negative subgroup, (C) ACPA-positive subgroup and (D) ACPA-negative subgroup. The
figures in the plots are the proportions of patients without erosion progression ( erosion score40.5). Q2M: denosumab
60 mg every 2 months; Q3M: denosumab 60 mg every 3 months; Q6M: denosumab 60 mg every 6 months.
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TABLE 3 Changes in the erosion score from baseline to 12 months according to other risk factors
Denosumab
Placebo (N=88) 60 mg Q6M (N=85) 60 mg Q3M (N=82) 60 mg Q2M (N=85)
Baseline SJC
510
n 39 27 42 40
Mean (S.D.) 1.50 (3.61) 0.71 (1.40) 0.25 (0.64) 0.03 (0.53)
Median (Q1, Q3) 0.00 (0.00, 1.00) 0.00 (0.00, 1.50) 0.00 (0.00, 0.50) 0.00 (0.00, 0.00)
P-value  0.4747 0.038 0.0009
<10
n 49 58 40 45
Mean (S.D.) 0.59 (1.55) 0.07 (0.63) 0.03 (0.37) 0.14 (2.04)
Median (Q1, Q3) 0.00 (0.00, 0.50) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)
P-value  0.0228 0.0479 0.0186
Baseline CRP
51.0 mg/dl
n 21 13 13 11
Mean (S.D.) 1.69 (4.35) 0.89 (1.89) 0.42 (0.61) 0.32 (1.03)
Median (Q1, Q3) 0.00 (0.00, 2.00) 0.00 (0.00, 1.50) 0.00 (0.00, 1.00) 0.00 (0.50, 1.50)
P-value  0.6656 0.6310 0.3966
<1.0 mg/dl
n 67 72 69 74
Mean (S.D.) 0.77 (1.90) 0.16 (0.67) 0.09 (0.51) 0.05 (1.58)
Median (Q1, Q3) 0.00 (0.00, 1.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)
P-value  0.0213 0.0078 0.0002
Duration of RA
53 years
n 28 26 24 25
Mean (S.D.) 1.65 (4.20) 0.03 (0.64) 0.04 (0.55) 0.59 (2.63)
Median (Q1, Q3) 0.00 (0.00, 1.75) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)
P-value  0.1549 0.1746 0.1702
<3 years
n 60 59 58 60
Mean (S.D.) 0.68 (1.51) 0.37 (1.09) 0.18 (0.53) 0.13 (0.57)
Median (Q1, Q3) 0.00 (0.00, 0.75) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)
P-value  0.1036 0.0298 <0.0001
Baseline ESR
528 mm/h
n 33 23 26 29
Mean (S.D.) 1.88 (3.97) 0.81 (1.60) 0.42 (0.64) 0.03 (0.77)
Median (Q1, Q3) 0.00 (0.00, 2.00) 0.00 (0.00, 1.50) 0.00 (0.00, 1.00) 0.00 (0.00, 0.50)
P-value  0.4237 0.2920 0.0144
<28 mm/h
n 55 62 56 56
Mean (S.D.) 0.46 (1.23) 0.07 (0.50) 0.01 (0.42) 0.11 (1.80)
Median (Q1, Q3) 0.00 (0.00, 0.50) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)
P-value  0.0173 0.0081 0.0034
Glucocorticoid use
Present
n 37 36 37 37
Mean (S.D.) 1.37 (3.74) 0.33 (1.24) 0.23 (0.57) 0.07 (0.73)
Median (Q1, Q3) 0.00 (0.00, 0.50) 0.00 (0.00, 0.00) 0.00 (0.00, 0.50) 0.00 (0.00, 0.00)
P-value  0.1885 0.5262 0.0072
Absent
n 51 49 45 48
Mean (S.D.) 0.72 (1.51) 0.22 (0.74) 0.07 (0.50) 0.20 (1.92)
Median (Q1, Q3) 0.00 (0.00, 1.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)
P-value  0.0307 0.0023 0.0041
The erosion score was assessed using the van der Heijde modified Sharp method. P-values were calculated using the two-
sided van Elteren stratified rank test adjusted for randomized strata (four strata according to the combination of baseline
glucocorticoid use and baseline RF) vs placebo. Q2M: denosumab 60 mg every 2 months; Q3M: denosumab 60 mg every
3 months; Q6M: denosumab 60 mg every 6 months; N: number of patients who received 51 dose of the investigational
product and had baseline measurement and at least one post-baseline measurement of the radiographic score; n: number
of patients in the subgroup; SJC: swollen joint count; Q1, Q3: quartile 1, 3.
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